Video

Dr. Goy on Immunotherapy in Mantle Cell Lymphoma

Andre Goy, MD, MS, chief, Division of Lymphoma, chairman and director, John Theurer Cancer Center, discusses the potential of immunotherapy in patients with mantle cell lymphoma (MCL).

Andre Goy, MD, MS, chief, Division of Lymphoma, chairman and director, John Theurer Cancer Center, discusses the potential of immunotherapy in patients with mantle cell lymphoma (MCL).

Lenalidomide (Revlimid) and rituximab (Rituxan; R2) plus ibrutinib (Imbruvica) is a combination approach of immunotherapy and targeted therapy, explains Goy. At John Theurer Cancer Center, 71% of heavily pretreated patients with MCL experienced a complete response with the regimen. Additionally, a published study showed high response rates in patients with poor genetic risk factors.

Traditionally, when physicians think about immunotherapy, they think about chimeric antigen receptor T cells, says Goy. However, a lot remains unknown about the use of checkpoint inhibitors in MCL. Activity outside of primary mediastinal lymphoma and Hodgkin lymphoma has been relatively disappointing, explains Goy. However, there is a lot of potential with anti—CD47 antibodies that may enable physicians to give patients a biological induction, and subsequently consider immunotherapy in high-risk patients.

Related Videos
Leah Backhus, MD, MPH, FACS, professor, University Medical Line, Cardiothoracic Surgery, co-director, Thoracic Surgery Clinical Research Program, associate program director, Thoracic Track, CT Surgery Residency Training Program, Thelma and Henry Doelger Professor of Cardiovascular Surgery, Stanford Medicine; chief, Thoracic Surgery, VA Palo Alto
Roy S. Herbst, MD, PhD, Ensign Professor of Medicine (Medical Oncology), professor, pharmacology, deputy director, Yale Cancer Center; chief, Medical Oncology, director, Center for Thoracic Cancers, Yale Cancer Center and Smilow Cancer Hospital; assistant dean, Translational Research, Yale School of Medicine
Chirag Shah, MD
Jason A. Mouabbi, MD
Roger Li, MD,
Brian I. Rini, MD, FASCO
Marc-Oliver Grimm, MD
David Samuel Dicapua Siegel, MD
Moritz Fürstenau, MD
Joseph Franses, MD, PhD